To test this, we performed a sub-chronic treatment with the CB1R agonist WIN over a 10-day period at two different stages of HD progression: 11 weeks, before cognitive symptoms are apparent and 13 weeks, when cognitive decline has already manifested [29, 30]. This evidence concerns the gene CNR1 and Huntington disease.